Normal Pressure Hydrocephalus Treatment by Acetazolamide

Normal pressure hydrocephalus (NPH) is an uncommon cause of dementia possibly reversible with treatment. First described in 1965 it consists of a triad of gait disturbance, cognitive deterioration, and urinary incontinence together with enlarged cerebral ventricles and normal cerebrospinal fluid (CSF) pressure. Foregoing trauma and hemorrhage, infection, mass lesions, or aqueductal stenosis can contribute to hydrocephalus. These symptomatic or secondary forms of NPH are not considered here and the focus lies on the idiopathic type (iNPH). Prevalence of iNPH increases significantly with age. General estimates range from 21.9 per 100,000 in total population surveys but increase up to 181.7 per 100,000 for people 70 to 79 years of age. The clinical presentation varies significantly in severity and progression of symptoms. For diagnosis the entire triad does not have to be present. In typical cases gait and balance disturbances appear either before or concurrently with urinary incontinence or the onset of dementia. Current treatment recommendations are based on surgical diversion of CSF , with shunts placed either into the ventricular system or the lumbar subarachnoid space to a distal site, such as the peritoneal or the pleural cavity or the venous system, where the CSF can be reabsorbed . Even though immediate response rate to shunt treatment might be favorable and rates of 80% responders have been reported , the perioperative and long-term morbidity and mortality of CSF shunting procedures are significant. A meta-analysis of 44 articles found that the pooled, mean rate of shunt complication was 38% . Even though acute surgical complication rates are low, shunt dysfunctions and long-term complications are relatively common. Shunt malfunction (20%), subdural hematoma (2-17%), seizure (3-11%), shunt infection (3-6%) and intracerebral hematoma (3%) are the most common complications . In those with good long-term survival, sustained improvement is possible, with a rate of 39% documented after 5 years .In view of the complication rates, the lack of alternative treatment options and clinical studies is surprising. Even though iNPH per definition lacks raised intracranial pressure on spinal tap, monitoring of ICP prior to surgery reveals an increased amount of brief (usually 30 seconds to 1 minute) increases in the static ICP, called Lundberg B waves, in patients which improve by shunt placements . When patients are scheduled for shunt treatment there is a waiting period of several weeks between diagnosis and operation due to congested waiting list.

Acetazolamide (Diamox) has been shown to reduce the production of CSF in clinical cases of raised intracranial pressure . It is considered the drug of choice for the treatment of idiopathic intracranial pressure (pseudotumor cerebri). Intuitively a connection between Acetazolamide as a treatment option in iNPH seems logical. Encouraging case studies have been published previously showing a fascinating improvement and success of treating iNPH with Acetazolamide. A systematic placebo controlled study concerning the use of Acetazolamide in iNPH is missing and would possibly pave the way to an alternative treatment option avoiding surgery and its complications.

Study Overview

• Status: Terminated
• Conditions: Motor Condition as Measured by Quantified Scale; Cognitive Investigation
• Intervention / Treatment: Drug: Acetazolamide; Drug: sugar pill

• Study Type: Interventional
• Enrollment (Actual): 2
• Phase: Phase 3

Contacts and Locations

Study Locations

• Israel
  • Hamerkaz
    • Petach Tiqva, Hamerkaz, Israel, 49100
      • Rabin Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 60 years to 80 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Included will be subjects with a probable diagnosis of iNPH. The diagnosis will be based primarily on presence of gait impairment plus at least one other impairment in urinary symptoms, cognition impairment or both.

1. Are 60 years old or older
2. Patients who understand the study protocol

3. Patients who meet the criteria for NPH

   1. A typical personal history
   2. A typical brain imaging on head CT or MRI
   3. Normal LP findings excluding other conditions
   4. Exclusion of other conditions causing the symptomatology
   5. Patients who underwent Continuous lumbar drainage or spinal tap which improved symptomatology.

Exclusion Criteria:

1. Patients below the age of 60 years.
2. Patients who underwent shunt surgery
3. Patients with a concurrent diagnosis of a neurodegenerative or neurovascular disease that causes a significant impairment of gait and cognitive functions
4. Patients with symptom duration of more than 6 month

5. Patients with contraindications for acetazolamide treatment:

   • Cirrhosis or marked liver disease or dysfunction
   • hyperchloremic acidosis
   • hypersensitivity to acetazolamide or any component of the product
   • hypersensitivity to sulfonamides or other sulfonamide derivatives, as cross-sensitivity may occur
   • hypokalemia
   • hyponatremia
   • renal dysfunction or disease
   • suprarenal gland failure

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NON_RANDOMIZED
• Interventional Model: PARALLEL
• Masking: DOUBLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
ACTIVE_COMPARATOR: Acetazolamide; active comparator group will receives 500 mg azetazolamide daily	Drug: Acetazolamide
PLACEBO_COMPARATOR: sugar pill; placebo comparator group will receives placebo daily.	Drug: sugar pill

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
1. Changes from baseline in motor on the Boon scale at week 4	The effect of acetazolamide on motor and cognitive function in iNPH patients will be examined. Motor system investigations - Gait assessment using a quantified scale (Boon et al., 1997). Scores from this metric represent 3 summed subscores: 10-m step count, 10-m time, and the following 10 features: hesitation, wide and small steps, low clearance, impaired turning, sway, fall tendency, impaired tandem walking, and inability to walk with and without assistance. The summed score has a range from 2-40, with 2 representing unimpaired gait.	Baseline, Week4

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes from baseline in cognitive function on the Mattis Dementia Rating Scale (MDRS) and the Montreal Cognitive Assessment (MoCA)	Cognitive tests -Mattis Dementia Rating Scale (MDRS) and Montreal Cognitive Assessment (MoCA) will be performed by our neuropsychology staff.	Baseline, week4

Collaborators and Investigators

• Sponsor: Rabin Medical Center

Study record dates

Study Major Dates

• Study Start: June 1, 2014
• Primary Completion (ACTUAL): January 1, 2017
• Study Completion (ACTUAL): January 1, 2017

Study Registration Dates

• First Submitted: April 13, 2014
• First Submitted That Met QC Criteria: June 12, 2014
• First Posted (ESTIMATE): June 13, 2014

Study Record Updates

• Last Update Posted (ACTUAL): April 13, 2017
• Last Update Submitted That Met QC Criteria: April 12, 2017
• Last Verified: April 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Carbonic Anhydrase Inhibitors; Natriuretic Agents; Diuretics; Anticonvulsants; Acetazolamide
• Other Study ID Numbers: IS 05 - 12